SINO BIOPHARM (01177) Completes First Patient Enrollment in Phase I Clinical Trial for Innovative Drug TRD208 in China

Stock News12-01

SINO BIOPHARM (01177) announced that the first patient enrollment for the Phase I clinical trial of its self-developed Class 1 innovative drug TRD208 in China has been successfully completed. TRD208 is a globally first-in-class non-opioid, multi-target, multimodal analgesic drug with the potential to become a blockbuster treatment for acute pain.

Preclinical data indicate that TRD208 demonstrates rapid onset, potent analgesic effects, and long-lasting efficacy in postoperative pain models. As a non-opioid drug with multi-target synergistic effects, TRD208 is expected to achieve multimodal analgesia with a single drug for the first time, potentially replacing current mainstream combination therapies. This innovation could simplify treatment regimens, improve patient compliance, and eliminate risks associated with opioid addiction and dependence.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment